Table 3. Multivariate analyses of prognostic factors for progression-free survival.

Variable	HR	95% CI	p-value
IFH	756.997	2.047-279,923.191	0.028
FIGO stage*	1.817	0.418-7.911	0.426
MTVtumor	0.981	0.946-1.017	0.293
TLGtumor	1.005	0.999-1.011	0.118
SUVtumor	0.832	0.657-1.055	0.129
SUVLN	1.056	0.956-1.165	0.283

FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; IFH, intratumoral [¹⁸F]fluorodeoxyglucose (FDG) uptake heterogeneity; LN, lymph node; MTV, metabolic tumor value; PFS, progression-free survival; SUV, standardized uptake value; TLG, total lesion glycolysis.

*Test for PFS: II vs. I.